Addendum
Nivolumab (melanoma) -Addendum to Commission A18-53
Report documents
-
Addendum
Nivolumab (melanoma) -Addendum to Commission A18-53
Dossier assessment
Indication:
Adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection
Result of dossier assessment:
Stage IIIB/C and IV disease: now hint of non-quantifiable added benefit. Stage IIIA disease: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2019-02-21 A G-BA decision was published.
Project details
- Project no.
- A19-01
- Commission
- Commission awarded on 07.01.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed